Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery

Total Page:16

File Type:pdf, Size:1020Kb

Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery SURGICAL INFECTIONS Volume 14, Number 1, 2013 Surgical Infection Mary Ann Liebert, Inc. DOI: 10.1089/sur.2013.9999 Society Guidelines Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery Dale W. Bratzler,1 E. Patchen Dellinger,2 Keith M. Olsen,3 Trish M. Perl,4 Paul G. Auwaerter,5 Maureen K. Bolon,6 Douglas N. Fish,7 Lena M. Napolitano,8 Robert G. Sawyer,9 Douglas Slain,10 James P. Steinberg,11 and Robert A. Weinstein12 hese guidelines were developed jointly by the Ameri- the project. Panel members and contractors were required to Tcan Society of Health-System Pharmacists (ASHP), the disclose any possible conflicts of interest before their ap- Infectious Diseases Society of America (IDSA), the Surgical pointment and throughout the guideline development pro- Infection Society (SIS), and the Society for Healthcare Epide- cess. Drafted documents for each surgical procedural section miology of America (SHEA). This work represents an update were reviewed by the expert panel and, once revised, were to the previously published ASHP Therapeutic Guidelines on available for public comment on the ASHP website. After Antimicrobial Prophylaxis in Surgery [1], as well as guide- additional revisions were made to address reviewer com- lines from IDSA and SIS [2,3]. The guidelines are intended to ments, the final document was approved by the expert panel provide practitioners with a standardized approach to the and the boards of directors of the above-named organizations. rational, safe, and effective use of antimicrobial agents for the prevention of surgical site infections (SSIs) based on currently Strength of evidence and grading of recommendations available clinical evidence and emerging issues. The primary literature from the previous ASHP Therapeutic Prophylaxis refers to the prevention of an infection and can Guidelines on Antimicrobial Prophylaxis in Surgery [1] was be characterized as primary prophylaxis, secondary prophy- reviewed together with the primary literature published be- laxis, or eradication. Primary prophylaxis refers to the pre- tween the date of the previous guidelines, 1999, and June 2010, vention of an initial infection. Secondary prophylaxis refers to identified by searches of MEDLINE, EMBASE, and the Co- the prevention of recurrence or reactivation of a preexisting chrane Database of Systematic Reviews. Particular attention infection. Eradication refers to the elimination of a colonized was paid to study design, with greatest credence given to organism to prevent the development of an infection. These randomized, controlled, double-blind studies. There is a lim- guidelines focus on primary perioperative prophylaxis. ited number of adequately powered randomized controlled trials evaluating the efficacy of antimicrobial prophylaxis in Guidelines development and use surgical procedures. Guidelines development included con- Members of ASHP, IDSA, SIS, and SHEA were appointed sideration of the following characteristics: validity, reliability, to serve on an expert panel established to ensure the validity, clinical applicability, flexibility, clarity, and a multidisciplinary reliability, and utility of the revised guidelines. The work of nature as consistent with ASHP’s philosophy on therapeutic the panel was facilitated by faculty of the University of guidelines [4]. The limitations of the evidence base are noted Pittsburgh School of Pharmacy and University of Pittsburgh within each individual procedure section of the guidelines. Medical Center Drug Use and Disease State Management Published guidelines with recommendations by experts in a Program who served as contract researchers and writers for procedure area (e.g., American College of Obstetricians and 1College of Public Health, and Professor, College of Medicine, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma. 2Department of Surgery, and Chief, Division of General Surgery, University of Washington, Seattle, Washington. 3Nebraska Medical Center, Omaha, Nebraska. 4Pathology, and Epidemiology, Johns Hopkins University, and Senior Epidemiologist, The Johns Hopkins Health System, Baltimore, Maryland. 5Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 6Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 7Department of Clinical Pharmacy, University of Colorado, Anschultz Medical Campus, and Clinical Specialist, Critical Care/Infectious Diseases, Department of Pharmacy Services, University of Colorado Hospital, Aurora, Colorado. 8Acute Care Surgery, Trauma, Burn, Critical Care, Emergency Surgery, and Associate Chair of Surgery, Critical Care, Department of Surgery, and Director, Surgical Critical Care, University of Michigan Health System, Ann Arbor, Michigan. 9Public Health Sciences, and Chief, Division of Acute Care Surgery and Outcomes Research, University of Virginia Health System, Charlottesville, Virginia. 10Pharmacy and Medicine, West Virginia University, Morgantown, West Virginia. 11Division of Infectious Diseases, Emory University, Atlanta, Georgia. 12Rush Medical College, Chicago, and Chairman, Department of Medicine, Cook County Health and Hospital System, Chicago, Illinois. Copyright ª 2013, American Society of Health-System Pharmacists, Inc. All rights reserved. 1079-2082/13/0201-0195$06.00. 73 74 SURGICAL PROPHYLAXIS GUIDELINES Gynecologists [ACOG]) and noted general guidelines (e.g., U.S. Preoperative-dose timing. The optimal time for admin- Centers for Disease Control and Prevention [CDC], Scottish istration of preoperative doses is within 60 min before surgi- Intercollegiate Guidelines Network, Medical Letter,SIS,SHEA/ cal incision. This is a more-specific time frame than the IDSA) were also considered [2,3,5–11]. previously recommended time, which was ‘‘at induction of Recommendations for the use of antimicrobial prophylaxis anesthesia.’’ Some agents, such as fluoroquinolones and are graded according to the strength of evidence available. The vancomycin, require administration over one to two hours; strength of evidence represents only support for or against therefore, the administration of these agents should begin prophylaxis and does not apply to the antimicrobial agent, dose, within 120 min before surgical incision. or dosage regimen. Studies supporting the recommendations for the use of antimicrobial therapy were classified as follows: Selection and dosing. Information is included regarding the approach to weight-based dosing in obese patients and the Level I (evidence from large, well-conducted, random- need for repeat doses during prolonged procedures [13–18]. ized, controlled clinical trials or a meta-analysis), Obesity has been linked to an increased risk for SSI. The Level II (evidence from small, well-conducted, ran- pharmacokinetics of drugs may be altered in obese patients, so domized, controlled clinical trials), dosage adjustments based on body weight may be warranted Level III (evidence from well-conducted cohort studies), in these patients. For all patients, intraoperative redosing is Level IV (evidence from well-conducted case–control needed to ensure adequate serum and tissue concentrations of studies), the antimicrobial if the duration of the procedure exceeds two Level V (evidence from uncontrolled studies that were half-lives of the drug or there is excessive blood loss during the not well conducted), procedure (Table 1). Recommendations for selection of anti- Level VI (conflicting evidence that tends to favor the microbial agents for specific surgical procedures and alterna- recommendation), or tive agents (e.g., for patients with allergies to b-lactam Level VII (expert opinion or data extrapolated from antimicrobials) are provided in Table 2. evidence for general principles and other procedures). Duration of prophylaxis. This system has been used by the Agency for Healthcare New recommendations for a Research and Quality, and ASHP, IDSA, SIS, and SHEA shortened postoperative course of antimicrobials involving a support it as an acceptable method for organizing strength of single dose or continuation for less than 24 hours are pro- evidence for a variety of therapeutic or diagnostic recom- vided. Further clarity on the lack of need for postoperative mendations [4]. Each recommendation was categorized ac- antimicrobial prophylaxis based on the presence of indwell- cording to the strength of evidence that supports the use or ing drains and intravascular catheters is included. nonuse of antimicrobial prophylaxis as category A (levels Common principles. A section addressing concepts that I–III), category B (levels IV–VI), or category C (level VII). apply to all types of surgical procedures has been added. When higher-level data are not available, a category C Expanded and new recommendations are provided for plas- recommendation represents a consensus of expert panel tic, urology, cardiac, and thoracic procedures, as well as members based on their clinical experience, extrapolation clarity on prophylaxis when implantable devices are inserted. from other procedures with similar microbial or other clinical The latest information on the use of mupirocin and on the role features, and available published literature. In these cases, the of vancomycin in surgical prophylaxis is summarized in these expert panel also extrapolated general principles and evi- updated guidelines. dence from other procedures. Some recommendations in- clude alternative approaches in situations in which panel Application of
Recommended publications
  • Thoracic Actinomycosis P
    Thorax (1973), 28, 73. Thoracic actinomycosis P. R. SLADE, B. V. SLESSER, and J. SOUTHGATE Groby Road Hospital, Leicester Six cases of pulmonary infection with Actinomyces Israeli and one case of infection with Nocardia asteroides are described. The incidence of thoracic actinomycosis has declined recently and the classical presentation with chronic discharging sinuses is now uncommon. The cases described illustrate some of the forms which the disease may take. Actinomycotic infection has been noted, not infrequently, to co-exist with bronchial carcinoma and a case illustrating this association is described. Sputum cytology as practised for the diagnosis of bronchial carcinoma has helped to identify the fungi in the sputum. Treatment is discussed, particularly the possible use of oral antibiotics rather than penicillin by injection. Actinomycosis is not common in this country. showed only submucosal fibrosis. Cytological exam- The Table shows the number of cases reported to ination of the sputum showed the presence of fungus Health Laboratory Service from public (Figs 2 and 3) and cultures gave a growth of the Public Actinomyces Israeli. The patient was hypersensitive to health and hospital laboratories in the United penicillin and was treated with oral tetracycline, 2 g Kingdom and Republic of Ireland in recent years. daily for six months. There was marked reduction It is usually considered that the chest may be in the shadowing on the chest film after only six involved in about 15% of cases (Cecil and Loeb, weeks of treatment (Fig. 4) and subsequently com- 1963). But, of the 36 cases reported in 1970, the plete disappearance. The patient has remained well chest was involved in only one case.
    [Show full text]
  • Quantitative Sputum Culture As a Means of Excluding False Positive Reports in the Routine Microbiology Laboratory
    J Clin Pathol: first published as 10.1136/jcp.25.8.697 on 1 August 1972. Downloaded from J. clin. Path., 1972, 25, 697-700 Quantitative sputum culture as a means of excluding false positive reports in the routine microbiology laboratory M. J. B. WILSON AND D. E. MARTIN From the Department of Microbiology, Royal Perth Hospital, Perth, Western Australia SYNOPSIS A relatively simple technique for sputum homogenization and dilution is described. Results show that this technique is reliable for isolation and quantitative culture of organisms from cases of chest infection. The technique has resulted in significant reduction in false positive reports, particularly when a system of interpretative reporting is utilized based on 107 organisms per millilitre of sputum being accepted as evidence of significant infection. The bacteriology of human excretions, particularly A critical analysis of sputum culture results from sputum and urine, has given rise to considerable our laboratory showed that there was frequently a difficulties in interpretation. Kass (1957) contributed good growth of a potential pathogen when clinical much to the better understanding of the significance evidence for infection was equivocal and there was a of non-catheter urine culture when he introduced the tendency for the laboratory to make an excessive copyright. concept of colony counts, in an effort to distinguish number of false positive reports using standard between infected urine and urine from normal culture methods. These false positive reports are persons contaminated by urethral flora. Lower misleading and make it difficult to manage cases respiratory tract infections may likewise show a effectively, and they may lead to unwarranted and heavy growth of commensal organisms, because of undesirable antibiotic usage.
    [Show full text]
  • Gas-Phase Broadband Spectroscopy Using Active Sources: Progress, Status, and Applications [Invited]
    104 Vol. 34, No. 1 / January 2017 / Journal of the Optical Society of America B Review Gas-phase broadband spectroscopy using active sources: progress, status, and applications [Invited] 1, 1,4 2 2 KEVIN C. COSSEL, *ELEANOR M. WAXMAN, IAN A. FINNERAN, GEOFFREY A. BLAKE, 3 1 JUN YE, AND NATHAN R. NEWBURY 1National Institute of Standards and Technology, 325 Broadway, Boulder, Colorado 80305, USA 2Division of Chemistry & Chemical Engineering, California Institute of Technology, Pasadena, California 91125, USA 3JILA, National Institute of Standards and Technology and University of Colorado, Department of Physics, University of Colorado, Boulder, Colorado 80309, USA 4e-mail: [email protected] *Corresponding author: [email protected] Received 19 September 2016; revised 1 November 2016; accepted 15 November 2016; posted 15 November 2016 (Doc. ID 275946); published 14 December 2016 Broadband spectroscopy is an invaluable tool for measuring multiple gas-phase species simultaneously. In this work we review basic techniques, implementations, and current applications for broadband spectroscopy. We discuss com- ponents of broadband spectroscopy including light sources, absorption cells, and detection methods and then discuss specific combinations of these components in commonly used techniques. We finish this review by discussing po- tential future advances in techniques and applications of broadband spectroscopy. © 2016 Optical Society of America OCIS codes: (300.1030) Absorption; (120.6200) Spectrometers and spectroscopic instrumentation; (120.4640) Optical instruments; (300.6390) Spectroscopy, molecular. https://doi.org/10.1364/JOSAB.34.000104 1. INTRODUCTION spectral bandwidth allows for the simultaneous detection of Molecular spectroscopy has been shown to be a powerful multiple species. This enables a single instrument to serve many analytical tool with a wide range of applications.
    [Show full text]
  • Specimen Collection: Sputum (Home Health Care) - CE
    Specimen Collection: Sputum (Home Health Care) - CE ALERT Don appropriate personal protective equipment (PPE) based on the patient’s signs and symptoms and indications for isolation precautions. Bronchospasm or laryngospasm, as a result of suctioning, can be severe and prolonged, and, in some cases, can be life-threatening without intervention. OVERVIEW Sputum is produced by cells that line the respiratory tract. Although production is minimal in the healthy patient, disease processes can increase the amount or change the character of sputum. Examination of sputum aids in the diagnosis and treatment of many conditions such as bronchitis, bronchiectasis, tuberculosis (TB), pneumonia, and pulmonary abscess, or lung cancer.3 In many cases, suctioning is indicated to collect sputum from a patient who cannot spontaneously produce a sample for laboratory analysis. Suctioning may provoke violent coughing, induce vomiting, and result in aspiration of stomach contents. Suctioning may also induce constriction of the pharyngeal, laryngeal, and bronchial muscles. In addition, suctioning may cause hypoxemia or vagal overload, causing cardiopulmonary compromise and an increase in intracranial pressure. Sputum for cytology, culture and sensitivity, and acid-fast bacilli (AFB) are three major types of sputum specimens.3 Cytologic or cellular examination of sputum may identify aberrant cells or cancer. Sputum collected for culture and sensitivity testing can be used to identify specific microorganisms and determine which antibiotics are the most sensitive. The AFB smear is used to support a diagnosis of TB. A definitive diagnosis of TB also requires a sputum culture and sensitivity.3 Regardless of the test ordered, a sputum specimen should be collected first thing in the morning due to a greater accumulation of bronchial secretions overnight.
    [Show full text]
  • 11736 Lab Req Red-Blue
    3550 W. Peterson Ave., Ste. 100 ACCOUNT: Chicago, Illinois 60659 Tel: 773-478-6333 Fax: 773-478-6335 LABORATORY REQUISITION PATIENT NAME - LAST FIRST MIDDLE INITIAL PATIENT IDENTIFICATION SOCIAL SECURITY NO. DATE OF BIRTH SEX N O I NAME OF INSURED SS# OF INSURED RELATIONSHIP TO PATIENT T A M R O PATIENT/INSURED ADDRESS PHONE NUMBER MEDICARE NO. (INCLUDING ALPHA CHARACTERS) F Please attach an ABN form. N I G N CITY STATE ZIP CODE I L L I MEDICAID NO. B BILL I PHYSICIAN I PATIENT I MEDICARE I MEDICAID I INSURANCE (attach copy of both sides of card) TO ACCOUNT DIAGNOSIS (CD-9 CODE(S)) (REQUIRED FOR 3RD PARTY BILLING) PLEASE WRITE PATIENT’S NAME ON ALL SPECIMENS DATE COLLECTED COLLECTED BY AM DR. NAME / NPI # DR. OR RN SIGNATURE PM 001 GENERAL HEALTH PROFILE ( Male ) - CBC, CMP, LIPID, TSH, FT4, TT3, FERRITIN, PSA, H-PYLORI, MAG, ESR, UA, IRON/TIBC SST, L, U 002 GENERAL HEALTH PROFILE ( Female ) - CBC, CMP, LIPID, TSH, FT4, TT3, FERRITIN, H-PYLORI, MAG, ESR, UA, IRON/TIBC SST, L, U 003 AMENOR/MENSTR. DISORDER - CMP, LIPID, CBC, TSH, FT4, TT3, ESR, IRON/TIBC, FERRITIN, MAG, UA, HCG, FSH, LH, PROLACTIN, RET COUNT SST, L, U 004 ANEMIA - CMP, LIPID, IRON/TIBC, CBC, FERRITIN, TSH, FT4, TT3, H-PYLORI, UA, G6PD, RET COUNT SST, L, U 005 ARTHRITIS - CMP, LIPID, CBC, URIC ACID, ESR, ASO, CRP, ANA, RH, SLE SST, L, U 006 DIABETES - CMP, LIPID, CBC, HBA1C, CORTISOL, TSH, FT4, TT3, UA, RET COUNT SST, L, U 007 HEPATITIS - HAAB IGM, HBCAB IGM, HBSAB, HBSAG, HCAB, SGOT, SGPT SST 008 HYPERTENSION/CARDIAC - CMP, LIPID, CBC, TSH, FT4, TT3, IRON/TIBC, CPK, CORTISOL,
    [Show full text]
  • Antimicrobial Treatment Guidelines for Common Infections
    Antimicrobial Treatment Guidelines for Common Infections March 2019 Published by: The NB Provincial Health Authorities Anti-infective Stewardship Committee under the direction of the Drugs and Therapeutics Committee Introduction: These clinical guidelines have been developed or endorsed by the NB Provincial Health Authorities Anti-infective Stewardship Committee and its Working Group, a sub- committee of the New Brunswick Drugs and Therapeutics Committee. Local antibiotic resistance patterns and input from local infectious disease specialists, medical microbiologists, pharmacists and other physician specialists were considered in their development. These guidelines provide general recommendations for appropriate antibiotic use in specific infectious diseases and are not a substitute for clinical judgment. Website Links For Horizon Physicians and Staff: http://skyline/patientcare/antimicrobial For Vitalité Physicians and Staff: http://boulevard/FR/patientcare/antimicrobial To contact us: [email protected] When prescribing antimicrobials: Carefully consider if an antimicrobial is truly warranted in the given clinical situation Consult local antibiograms when selecting empiric therapy Include a documented indication, appropriate dose, route and the planned duration of therapy in all antimicrobial drug orders Obtain microbiological cultures before the administration of antibiotics (when possible) Reassess therapy after 24-72 hours to determine if antibiotic therapy is still warranted or effective for the given organism
    [Show full text]
  • Diagnostic Value of Bronchoalveolar Lavage in the Subset of Patients With
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Qatar University Institutional Repository International Journal of Infectious Diseases 82 (2019) 96–101 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Diagnostic value of bronchoalveolar lavage in the subset of patients with negative sputum/smear and mycobacterial culture and a suspicion of pulmonary tuberculosis a b, c c Mushtaq Ahmad , Wanis H. Ibrahim *, Sabir Al Sarafandi , Khezar S. Shahzada , c c d e c Shakeel Ahmed , Irfan Ul Haq , Tasleem Raza , Mansoor Ali Hameed , Merlin Thomas , c c Hisham Ab Ib Swehli , Hisham A. Sattar a Department of Medicine, Hamad General Hospital, Weill-Cornell Medical College, Doha, Qatar b Hamad General Hospital, Qatar University and Weill-Cornell Medical College, Doha, Qatar c Department of Medicine, Hamad General Hospital, Doha, Qatar d Hamad General Hospital, Weill-Cornell Medical College, Doha, Qatar e Hamad General Hospital, Doha, Qatar A R T I C L E I N F O A B S T R A C T Article history: Background: The diagnostic value of bronchoalveolar lavage in patients with negative sputum/smear for Received 31 January 2019 tuberculous bacilli has been well studied. However, its value in the subset of patients with both negative Received in revised form 10 March 2019 sputum/smear and culture is seldom reported. Accepted 14 March 2019 Methods: A retrospective study of patients referred for diagnostic bronchoscopy for the suspicion of Corresponding Editor: Eskild Petersen, Aar- pulmonary tuberculosis during the period from April 1st, 2015 to March 30th, 2016, and who had hus, Denmark negative sputum/smear and culture for tuberculous bacilli.
    [Show full text]
  • Video Thoracoscopic Surgery Used to Manage Tuberculosis in Thoracic Surgery
    Surg Endosc (2005) 19: 1341–1344 DOI: 10.1007/s00464-004-2130-6 View metadata,Ó Springer citation Science+Business and similar papers Media, at core.ac.uk Inc. 2005 brought to you by CORE provided by RERO DOC Digital Library Video thoracoscopic surgery used to manage tuberculosis in thoracic surgery M. Beshay,1 P. Dorn,1 J. R. Kuester,1 G. L. Carboni,1 M. Gugger,2 R. A. Schmid1 1 Division of General Thoracic Surgery, University Hospital Berne, Berne, 3010, Switzerland 2 Institute of Pathology, University Hospital Berne, Berne, 3010, Switzerland Received: 7 June 2004/Accepted: 11 February 2005/Online publication: 23 June 2005 Abstract mised patients, especially human immuno deficiency Background: The aim of this study was to evaluate the virus (HIV) seropositive patients, or to increasing indications and results of video-assisted thoracic surgery immigration [2, 10, 11, 13]. Thus, it appears that the (VATS) for the management of tuberculosis in 10 pa- clinical and radiologic presentation of tuberculosis has tients with unusual clinical and radiologic presentation changed to more unusual manifestations. With the for the disease. dramatic improvement of video-assisted thoracic sur- Methods: From March 2000 to March 2002, 96 diag- gery (VATS), this approach for the diagnosis of different nostic VATS operations for unclear thoracic lesions thoracic lesions is recommended as standard, and is were performed at the authorsÕ institution. Their final becoming popular for the diagnosis of TB [15]. diagnosis for 10 (10.4%) of these patients was tubercu- Hans Christian Jacobaeus [4], a Swedish internist, is losis. The suspected preoperative diagnoses were pan- generally known as the first to undertake an endoscopic coast tumour (n = 1), pericardial effusion (n = 1), exploration of the thorax in 1910 to break pleural pleural mesothelioma (n = 1), pleural empyema adhesions with the patient under local anesthesia to (n = 2), mediastinal lymphoma (n = l), and lung can- facilitate collapse therapy for pulmonary tuberculosis.
    [Show full text]
  • Left Vocal Cord Paralysis After Mobilisation of the Internal Mammary Artery
    Thorax: first published as 10.1136/thx.43.11.941 on 1 November 1988. Downloaded from Thorax 1988;43:941-942 Left vocal cord paralysis after mobilisation of the internal mammary artery ROBERT R JEFFRY, BRIAN M FABRI, MARK A FOX From the Regional Adult Cardiothoracic Unit, Broadgreen Hospital, Liverpool ABSTRACT A case of vocal cord paralysis following heparinisation from its origin at the left subclavian artery to mobilisation of the internal mammary artery is des- its bifurcation with low current diathermy. Exposure was cribed. Of the various possible mechanisms, the most facilitated with a Favoloro sternal retractor. The internal likely in this case is damage to the vagus nerve in the mammary artery was anastomosed to the left anterior root of the neck, where it passes close to the origin of descending artery with 7/0 prolene and reversed saphenous vein was used for a further two grafts. the internal mammary artery. Diathermy may have His immediate postoperative condition was good and a caused the damage, and this may be avoided by using a postoperative chest radiograph showed that the end of the disposable automatic clip applier on any branches of endotracheal tube was just above the tracheal bifurcation. the mammary artery in the area. After an atraumatic extubation 16 hours after operation the patient was noted to be hoarse with a bovine cough. He developed a chest infection and sputum culture grew The left internal mammary artery is widely used in suitable Haemophilus influenzae. Indirect laryngoscopy on the 11th patients as the conduit for coronary revascularisation. We postoperative day showed paralysis ofthe left vocal cord.
    [Show full text]
  • Icd-9-Cm (2010)
    ICD-9-CM (2010) PROCEDURE CODE LONG DESCRIPTION SHORT DESCRIPTION 0001 Therapeutic ultrasound of vessels of head and neck Ther ult head & neck ves 0002 Therapeutic ultrasound of heart Ther ultrasound of heart 0003 Therapeutic ultrasound of peripheral vascular vessels Ther ult peripheral ves 0009 Other therapeutic ultrasound Other therapeutic ultsnd 0010 Implantation of chemotherapeutic agent Implant chemothera agent 0011 Infusion of drotrecogin alfa (activated) Infus drotrecogin alfa 0012 Administration of inhaled nitric oxide Adm inhal nitric oxide 0013 Injection or infusion of nesiritide Inject/infus nesiritide 0014 Injection or infusion of oxazolidinone class of antibiotics Injection oxazolidinone 0015 High-dose infusion interleukin-2 [IL-2] High-dose infusion IL-2 0016 Pressurized treatment of venous bypass graft [conduit] with pharmaceutical substance Pressurized treat graft 0017 Infusion of vasopressor agent Infusion of vasopressor 0018 Infusion of immunosuppressive antibody therapy Infus immunosup antibody 0019 Disruption of blood brain barrier via infusion [BBBD] BBBD via infusion 0021 Intravascular imaging of extracranial cerebral vessels IVUS extracran cereb ves 0022 Intravascular imaging of intrathoracic vessels IVUS intrathoracic ves 0023 Intravascular imaging of peripheral vessels IVUS peripheral vessels 0024 Intravascular imaging of coronary vessels IVUS coronary vessels 0025 Intravascular imaging of renal vessels IVUS renal vessels 0028 Intravascular imaging, other specified vessel(s) Intravascul imaging NEC 0029 Intravascular
    [Show full text]
  • I.G.I.M.S. Detail of Hospital Charges
    I.G.I.M.S. DETAIL OF HOSPITAL CHARGES CODE Room No TEST NAME RATE - OPD Paid Clinic DEPT. : 27 ADVANCE MAP # : 11 630124 0 ADDITIONAL CHARGES 10.00 20.00 630125 0 ADDITIONAL CHARGES 20.00 30.00 630126 0 ADDITIONAL CHARGES 30.00 50.00 630127 0 ADDITIONAL CHARGES 40.00 60.00 630128 0 ADDITIONAL CHARGES 10,000.00 15,000.00 630129 0 ADDITIONAL CHARGES 2,000.00 3,000.00 630130 0 ADDITIONAL CHARGES 3,000.00 4,500.00 630131 0 ADDITIONAL CHARGES 5,000.00 7,500.00 630132 0 ADDITIONAL CHARGES 4,000.00 6,000.00 630122 0 ADDITIONAL CHARGES 400.00 600.00 630114 0 ADDITIONAL CHARGES 50.00 80.00 630115 0 ADDITIONAL CHARGES 100.00 150.00 630116 0 ADDITIONAL CHARGES 200.00 300.00 630117 0 ADDITIONAL CHARGES 500.00 750.00 630118 0 ADDITIONAL CHARGES 1,000.00 1,500.00 630119 0 ADDITIONAL CHARGES 1,500.00 2,250.00 630111 0 ADDITIONAL CHARGES 3,600.00 5,400.00 630113 0 ADDITIONAL CHARGES 7,200.00 10,800.00 630112 0 ADDITIONAL CHARGES 4,800.00 7,200.00 630101 0 ADDITIONAL CHARGES 2,400.00 3,600.00 630105 0 ADDITIONAL CHARGES 6,000.00 9,000.00 630110 0 ADDITIONAL CHARGES 8,400.00 12,600.00 630133 0 ADDITIONAL CHARGES 6,400.00 9,600.00 630139 0 ADDITIONAL CHARGES 20,000.00 30,000.00 630140 0 ADDITIONAL CHARGES 25,000.00 37,500.00 630141 0 ADDITIONAL CHARGES 12,000.00 18,000.00 630134 0 ADV FOR EMERGENCY WARD 5,000.00 7,500.00 630107 0 ADV FOR GENERAL WARD 3,600.00 5,400.00 630108 0 ADV FOR ICU / VENTILATION 12,000.00 18,000.00 630103 0 ADV FOR PRIVATE WARD (NON A/C) 10,000.00 15,000.00 630102 0 ADV FOR RIO 1,200.00 1,800.00 630109 0 ADVANCE FOR DELUX ROOM 50,000.00 75,000.00 630137 0 ADVANCE FOR E-HDU 25,000.00 37,500.00 630136 0 ADVANCE FOR E-ICU 50,000.00 75,000.00 630104 0 ADVANCE FOR MINOR SURGERY 600.00 900.00 630106 0 ADVANCE FOR PHACO SURGERY 6,000.00 9,000.00 640117 0 ADVANCE FOR PICU 10,000.00 15,000.00 630135 0 ADVANCE FOR PRIVATE WARD (A/C) 15,000.00 22,500.00 630138 0 ADVANCE FOR RED ZONE 30,000.00 45,000.00 10-Jul-2019 * Test will be implemented soon.
    [Show full text]
  • Prevention of Neonatal Ventilator-Associated Pneumonia Through Oral Care with the Combined Use of Colostrum and Sodium Bicarbonate
    European Review for Medical and Pharmacological Sciences 2021; 25: 2361-2366 Prevention of neonatal ventilator-associated pneumonia through oral care with the combined use of colostrum and sodium bicarbonate D.-F. LI, C.-X. SHI, L. ZHAO, F.-Z. SHI, M.-L. JIANG, W.-Q. KANG Children’s Hospital Affiliated to Zhengzhou University, Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou, China Abstract. – OBJECTIVE: This study aims to Introduction investigate the effect of oral care via the com- bined use of colostrum and sodium bicarbonate With the popularization of ventilators in the on the prevention of neonatal ventilator-associ- neonatal intensive care unit (NICU), the success ated pneumonia (VAP). rate of neonatal rescue is evidently elevated. How- PATIENTS AND METHODS: In accordance with the inclusion and exclusion criteria, 120 in- ever, ventilator-associated pneumonia (VAP) has fant patients who were hospitalized in the neo- become a major acquired infection in hospitals natal intensive care unit (NICU) from January and the main complication of invasive mechan- to October of 2019 were selected and random- ical ventilation1. VAP lengthens the mechanical ly divided into three groups (40 cases in each ventilation time and the length of stay (LOS) of group), namely, colostrum combined with sodi- infant patients and increases the incidence rate of um bicarbonate nursing (experimental group), their complications, hospitalization expense, and colostrum (control group I), and sodium bi- mortality risk2,3, thereby seriously affecting neo- carbonate (control group II) groups. The pri- mary outcomes measured included incidence natal short- and long-term prognoses. According 4,5 rates of VAP and oral infection, positive rate of to previous studies , the domestic (China) and pathogenic bacteria after sputum culture, me- foreign VAP incidence rates are 30.0%-60.0% chanical ventilation time, and length of stay and 3.0%-28.3%, respectively.
    [Show full text]